Smagp fusion molecules and methods of use thereof
AssigneeDEM BioPharma, Inc.
InventorsLoise M. Francisco-Anderson, Sandeep Kumar, Sarah Elizabeth Carden, Christophe Quéva, Nenad Grmusa
Life of this patent
Estimating the term…
Abstract
Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.
Claims21
-164. (canceled)
A fusion molecule comprising a SMAGP extracellular domain (ECD) and one or more of a half-life extending moiety, a payload molecule, and a targeting moiety that binds to a target molecule on a cell.
A method of identifying a modulator, enhancer, or inhibitor of the interaction of SMAGP and CLEC10A or CD177, the method comprising:
- (a) measuring the binding of SMAGP to CLEC10A in the presence and absence of a test compound, wherein an increase or decrease in the amount of binding of SMAGP to CLEC10A in the presence of the test compound relative to the amount of binding of SMAGP to CLEC10A in the absence of the test compound identifies the test compound as a modulator of the interaction of SMAGP and CLEC10A, an increase in the amount of binding of SMAGP to CLEC10A in the presence of the test compound relative to the amount of binding of SMAGP to CLEC10A in the absence of the test compound identifies the test compound as an enhancer of the interaction of SMAGP and CLEC10A, and a decrease in the amount of binding of SMAGP to CLEC10A in the presence of the test compound relative to the amount of binding of SMAGP to CLEC10A in the absence of the test compound identifies the test compound as an inhibitor of the interaction of SMAGP and CLEC10A, optionally wherein the SMAGP and/or CLEC10A is expressed on the surface of cells or is a recombinant protein, further optionally wherein the recombinant protein is a fusion molecule comprising an Fc region;
- or
- (b) measuring the binding of SMAGP to CD177 in the presence and absence of a test compound, wherein an increase or decrease in the amount of binding of SMAGP to CD177 in the presence of the test compound relative to the amount of binding of SMAGP to CD177 in the absence of the test compound identifies the test compound as a modulator of the interaction of SMAGP and CD177, an increase in the amount of binding of SMAGP to CD177 in the presence of the test compound relative to the amount of binding of SMAGP to CD177 in the absence of the test compound identifies the test compound as an enhancer of the interaction of SMAGP and CD177, and a decrease in the amount of binding of SMAGP to CD177 in the presence of the test compound relative to the amount of binding of SMAGP to CD177 in the absence of the test compound identifies the test compound as an inhibitor of the interaction of SMAGP and CD177, optionally wherein the SMAGP and/or CD177 is expressed on the surface of cells or is a recombinant protein, further optionally wherein the recombinant protein is a fusion molecule comprising an Fc region;
- optionally wherein the test compound is selected from the group consisting of a small molecule, a polypeptide, or a nucleic acid, further optionally wherein the polypeptide is an antibody or the nucleic acid is a DNA or RNA aptamer,
- optionally wherein the amount of binding is measured using enzyme linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), or flow cytometry.
Dependencies are inferred from the claim text.